Hemochromatosis References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Jellinger K, Kienzl E, Rumpelmair G, et al. Iron-melanin complex in substantianigra of parkinsonian brains: an x-ray microanalysis. J. Neurochem. 1992;59(3):1168-1171.
  2. Kew MC. Hepatic iron overload and hepatocellular carcinoma. Cancer Lett. 2009;286(1):38-43.
  3. Shima T, Sarna T, Swartz HM, Stroppolo A, Gerbasi R, Zecca L. Binding of iron to neuromelanin of human substantianigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free RadicBiol Med. 1997;23(1):110-119.
  4. Siddique A and Kowdley KV. Review article: the iron overload syndromes. Aliment.Pharmacol.Ther. 2012;35(8):876-893.
  5. Huang X. Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res. 2003 Dec 10;533(1-2):153-71.
  6. Heli H, Mirtorabi S, Karimian K. Advances in iron chelation: an update. Expert OpinTher Pat. 2011;21(6):819-856.
  7. Cogswell ME, Looker AC, Pfeiffer CM, et al. Assessment of iron deficiency in US preschool children and nonpregnant females of childbearing age: National Health and Nutrition Examination Survey 2003-2006. Am J ClinNutr. 2009;89(5):1334-1342.
  8. Fleming DJ, Jacques PF, Tucker KL, et al. Iron status of the free-living, elderly Framingham Heart Study cohort: an iron-replete population with a high prevalence of elevated iron stores. Am J ClinNutr. 2001;73(3):638-646.
  9. Killilea DW, Atamna H, Liao C, et al. Iron accumulation during cellular senescence in human fibroblasts in vitro. Antioxid Redox Signal. 2003 Oct;5(5):507-16.
  10. Brittenham G. Hoffman: Hematology: Basic Principles and Practice, 5th ed (© 2008). CHAPTER 36 - DISORDERS OF IRON METABOLISM: IRON DEFICIENCY AND IRON OVERLOAD. Available at: http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-0-443-06715-0..50038-8&isbn=978-0-443-06715-0&sid=1318758387&uniqId=338101529-7#4-u1.0-B978-0-443-06715-0..50038-8 Accessed 6/5/2012.
  11. Borgaonkar MR. Hemochromatosis.More common than you think. Can Fam Physician. 2003;49:36-43.
  12. Fischer R and Harmatz PR. Non-invasive assessment of tissue iron overload. Hematology Am Soc Hematol Educ Program. 2009:215-221.
  13. Muñoz M, García-Erce JA, Remacha ÁF.Disorders of iron metabolism. Part II: iron deficiency and iron overload. J. Clin. Pathol. 2011;64(4):287-296.
  14. Fleming RE and Ponka P. Iron overload in human disease. N Engl J Med. 2012;366(4):348-359.
  15. Santos PC, Krieger JE, Pereira AC. Molecular diagnostic and pathogenesis of hereditary hemochromatosis. Int J Mol Sci. 2012;13(2):1497-1511.
  16. Murray KF, Lam D, Kowdley KV.Current and future therapy in haemochromatosis and Wilson's disease.Expert OpinPharmacother. 2003;4(12):2239-2251.
  17. Geissler C, Singh M. Iron, meat and health. Nutrients. 2011 Mar;3(3):283-316.
  18. Fisher J, Devraj K, Ingram J, et al. Ferritin: a novel mechanism for delivery of iron to the brain and other organs. Am J Physiol Cell Physiol. 2007;293(2):C641-9.
  19. Pietrangelo A. Hereditary Hemochromatosis: Pathogenesis, Diagnosis, and Treatment. Gastroenterology. 2010;139(2):393-408.e2.
  20. Marx JJ and van Asbeck BS.e of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage. ActaHaematol. 1996;95(1):49-62.
  21. Emerit J, Beaumont C, and Trivin F. Iron metabolism, free radicals, and oxidative injury.Biomed Pharmacother. 2001 Jul;55(6):333-9.
  22. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276(11):7811-7819.
  23. Brissot P, Ropert M, Le Lan C, Loréal, O. Non-transferrin bound iron: A key role in iron overload and iron toxicity. BiochimBiophysActa. 2012;1820(3):403-410.
  24. Sebastiani G and Walker AP. HFE gene in primary and secondary hepatic iron overload. World J Gastroenterol. 2007 Sep 21;13(35):4673-89.
  25. Gregory A and Hayflick SJ. Genetics of neurodegeneration with brain iron accumulation. CurrNeurolNeurosci Rep. 2011;11(3):254-261.
  26. Bring P, Partovi N, Ford JA, Yoshida EM. Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy. Pharmacotherapy. 2008;28(3):331-342.
  27. Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. Risk of cancer by transferrin saturation levels and haemochromatosis genotype: population-based study and meta-analysis. Journal of Internal Medicine. 2012;271(1):51-63.
  28. MedlinePlus 2010.Hypogonadism. Updated 10/14/2010. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/001195.htm. Accessed: 6/6/2012.
  29. Valenti L, Varenna M, Fracanzani AL, Rossi V, Fargion S, Sinigaglia L. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int. 2009;20(4):549-55.
  30. Kremastinos DT and Farmakis D. Iron overload cardiomyopathy in clinical practice. Circulation. 2011;124(20):2253-2263.
  31. Klintschar M and Stiller D. Sudden cardiac death in hereditary hemochromatosis: an underestimated cause of death? Int J Legal Med. 2004 Jun;118(3):174-7.
  32. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol. 2011;55(4):920-932.
  33. Williams R, Buchheit CL, Berman NE, LeVine SM. Pathogenic implications of iron accumulation in multiple sclerosis. J. Neurochem. 2012;120(1):7-25.
  34. Nandar W, Connor JR. HFE gene variants affect iron in the brain. J Nutr. 2011 Apr 1;141(4):729S-739S.
  35. Crichton RR, Dexter DT, Ward RJ. Brain iron metabolism and its perturbation in neurological diseases.J Neural Transm. 2011;118(3):301-314.
  36. Noetzli LJ, Panigrahy A, Mittelman SD, et al. Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol.2011 Nov 4. [Epub ahead of print]
  37. McDermott JH and Walsh CH. Hypogonadism in hereditary hemochromatosis.J ClinEndocrinolMetab. 2005 Apr;90(4):2451-5.
  38. Van deursen C, Delaere K, and Tenkate J. Hemochromatosis and sexual dysfunction.International Journal of Impotence Research (2003) 15:430-432.
  39. Walsh CH, Wright AD, Williams JW, Holder G A study of pituitary function in patients with idiopathic haemochromatosis.J ClinEndocrinolMetab (1976) 43:866-872.
  40. Gautier A, Lainé F, Massart C, et al. Liver iron overload is associated with elevated SHBG concentration and moderate hypogonadotrophichypogonadism in dysmetabolic men without genetic haemochromatosis. Eur J Endocrinol. 2011 Aug;165(2):339-43.
  41. Selby C. Sex hormone binding globulin: origin, function and clinical significance. Ann ClinBiochem. 1990 Nov;27 ( Pt 6):532-41.
  42. Rochira V, lestrieri A, Madeo B, et al. Osteoporosis and male age-related hypogonadism: role of sex steroids on bone (patho)physiology. Eur J Endocrinol. 2006 Feb;154(2):175-85.
  43. Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011 Nov;165(5):687-701.
  44. Dandona P and Dhindsa S. Update: Hypogonadotropichypogonadism in type 2 diabetes and obesity. J ClinEndocrinolMetab. 2011 Sep;96(9):2643-51.
  45. Dandona P and Rosenberg MT.A practical guide to male hypogonadism in the primary care setting.Int J ClinPract. 2010 May;64(6):682-96.
  46. Cundy T, Bomford A, Butler J, et al. Hypogonadism and sexual dysfunction in hemochromatosis: the effects of cirrhosis and diabetes. J ClinEndocrinolMetab. 1989 Jul;69(1):110-6.
  47. McCarthy GM, Crowe J, McCarthy CJ, et al. Hereditary hemochromatosis: a common, often unrecognized, genetic disease. ClevClin J Med. 2002 Mar;69(3): 224-6, 229-30, 232-3 passim.
  48. Taher A, El Rassi F, Isma'eel H, et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica. 2008 Oct;93(10):1584-6.
  49. vanDijk BA, Laarakkers CM, Klaver SM, et al. Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels. British Journal of Haematology. 2008;142(6):979-85.
  50. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood. 2011;117(25):e218-25.
  51. Hider RC and Zhou T.The design of orally active iron chelators. Ann N Y Acad Sci. 2005;1054:141-54.
  52. Hider RC.Potential protection from toxicity by oral iron chelators.Toxicol.Lett. 1995;82-83:961-967.
  53. Zhou T, Winkelmann G, Dai ZY, Hider RC. Design of clinically useful macromolecular iron chelators. J. Pharm. Pharmacol. 2011;63(7):893-903.
  54. Neufeld EJ, Galanello R, Viprakasit V, et al. A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload.Blood. 2012;119(14):3263-8.
  55. Preza GC, Ruchala P, Pinon R, et al. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest. 2011;121(12):4880-4888.
  56. Rombout-Sestrienkova E, Nieman FHM, Essers BAB, et al. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial. Transfusion. 2012;52(3):470-7.
  57. Di Bartolomeo P, Santarone S, Di Bartolomeo E, et al. Long-term results of survival in patients with thalassemia major treated with bone marrow transplantation. Am. J. Hematol. 2008;83(7):528-530.
  58. Morán-Jiménez MJ, García-Bravo M, Méndez M, et al. Bone marrow transplantation into hemochromatotic mice decreases hepatic and duodenal iron overload. Int. J. Biochem. Cell Biol. 2008;40(1):135-146.
  59. Milward EA, Baines SK, Knuiman MW, et al. Noncitrus fruits as novel dietary environmental modifiers of iron stores in people with or without HFE gene mutations. Mayo Clin. Proc. 2008;83(5):543-549.
  60. Cade JE, Moreton JA, O'Hara B, et al. Diet and genetic factors associated with iron status in middle-aged women. Am J ClinNutr. 2005;82(4):813-820.
  61. U.S. Department of Agriculture, Agricultural Research Service.2011. USDA National Nutrient Database for Standard Reference, Release 24.Nutrient Data Laboratory Home Page. Available at: http://www.ars.usda.gov/ba/bhnrc/ndl. Accessed 6/5/2012.
  62. Crawford RD. Proposed role for a combination of citric acid and ascorbic acid in the production of dietary iron overload: a fundamental cause of disease. Biochem. Mol. Med. 1995;54(1):1-11.
  63. Barton JC, McDonnell SM, Adams PC, et al. Management of Hemochromatosis. Ann Intern Med. 1998;129(11):932-39.
  64. Jiang R, Lopez V, Kelleher SL, et al. Apo- and holo-lactoferrin are both internalized by lactoferrin receptor via clathrin-mediated endocytosis but differentially affect ERK-signaling and cell proliferation in Caco-2 cells. J Cell Physiol. 2011 Nov;226(11):3022-31.
  65. Paesano R, Pietropaoli M, Gessani S, et al. The influence of lactoferrin, orally administered, on systemic iron homeostasis in pregnant women suffering of iron deficiency and iron deficiency anaemia. Biochimie. 2009 Jan;91(1):44-51.
  66. Brock JH. Lactoferrin—50 years on. Biochem Cell Biol. 2012 Jun;90(3):245-51.
  67. Scarino ML. A sideways glance: Take it or leave it? The role of lactoferrin in iron sequestration and delivery within the body. Genes Nutr. 2007 Nov;2(2):161-2.
  68. Mulder AM, Connellan PA, Oliver CJ, et al. Bovine lactoferrin supplementation supports immune and antioxidant status in healthy human males. Nutr Res. 2008 Sep;28(9):583-9.
  69. Baldwin DA, Jenny ER, Aisen P. The effect of human serum transferrin and milk lactoferrin on hydroxyl radical formation from superoxide and hydrogen peroxide. J Biol Chem.1984;259(21):13391-4.
  70. Kono Y, Kashine S, Yoneyama T, Sakamoto Y, Matsui Y, Shibata H. Iron chelation by chlorogenic acid as a natural antioxidant. BiosciBiotechnolBiochem. 1998;62(1):22-27.
  71. Guo M, Perez C, Wei Y, et al. Iron-binding properties of plant phenolics and cranberry's bio-effects. Dalton Trans. 2007;(43):4951-4961.
  72. Kulkarni AP, Mahal HS, Kapoor S, Aradhya SM.In vitro studies on the binding, antioxidant, and cytotoxic actions of punicalagin. J Agric Food Chem. 2007;55(4):1491-1500.
  73. Lin B, Johnson BJ, Rubin RA, Malanoski AP, Ligler FS. Iron chelation by cranberry juice and its impact on Escherichia coli growth. Biofactors. 2011;37(2):121-130.
  74. Mladěnka P, Macáková K, Filipský T, et al. In vitro analysis of iron chelating activity of flavonoids. J. Inorg. Biochem. 2011;105(5):693-701.
  75. Minakata K, Fukushima K, Nakamura M, Iwahashi H. Effect of some naturally occurring iron ion chelators on the formation of radicals in the reaction mixtures of rat liver microsomes with ADP, Fe and NADPH. J ClinBiochemNutr. 2011;49(3):207-215.
  76. Zhang Y, Li H, Zhao Y, Gao Z. Dietary supplementation of baicalin and quercetin attenuates iron overload induced mouse liver injury. European Journal of Pharmacology. 2006;535(1-3):263-269.
  77. Monnier L, Colette C, Aguirre L, Mirouze J. Evidence and mechanism for pectin-reduced intestinal inorganic iron absorption in idiopathic hemochromatosis. Am J ClinNutr. 1980;33(6):1225-1232.
  78. Borsari M, Gabbi C, Ghelfi F, et al. Silybin, a new iron-chelating agent. J. Inorg. Biochem. 2001;85(2-3):123-129.
  79. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010;24(10):1423-1432.
  80. Hutchinson C, Bomford A, Geissler CA.The iron-chelating potential of silybin in patients with hereditary haemochromatosis.Eur J ClinNutr. 2010;64(10):1239-1241.
  81. Bares JM, Berger J, Nelson JE, et al. Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C. J. Clin. Gastroenterol. 2008;42(8):937-944.
  82. Gharagozloo M, Moayedi B, Zakerinia M, et al. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial. FundamClinPharmacol. 2009;23(3):359-365.
  83. García CR, Angelé-Martínez C, Wilkes JA, Wang HC, Battin EE, Brumaghim JL. Prevention of iron- and copper-mediated DNA damage by catecholamine and amino acid neurotransmitters, l-DOPA, and curcumin: metal binding as a general antioxidant mechanism. Dalton Trans. 2012.
  84. Reddy AC and Lokesh BR. Effect of curcumin and eugenol on iron-induced hepatic toxicity in rats.Toxicology. 1996;107(1):39-45.
  85. Atamna H and Boyle K. Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. ProcNatlAcadSci USA. 2006;103(9):3381-3386.
  86. Thephinlap C, Phisalaphong C, Lailerd N, et al. Reversal of cardiac iron loading and dysfunction in thalassemic mice by curcuminoids. Med Chem. 2011;7(1):62-69.
  87. Thephinlap C, Phisalaphong C, Fucharoen S, Porter JB, Srichairatanakool S. Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice. Med Chem. 2009;5(5):474-482.
  88. Jiao Y, Wilkinson J, Di X, et al. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood. 2009;113(2):462-469.
  89. Jiao Y, Wilkinson J, Christine Pietsch E, et al. Iron chelation in the biological activity of curcumin. Free RadicBiol Med. 2006;40(7):1152-1160.
  90. Mandel S, Amit T, Reznichenko L, Weinreb O, Youdim MBH. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Mol. Nutr. Food Res. 2006;50(2):229-234.
  91. Srichairatanakool S, Ounjaijean S, Thephinlap C, Khansuwan U, Phisalpong C, Fucharoen S. Iron-chelating and free-radical scavenging activities of microwave-processed green tea in iron overload. Hemoglobin. 2006;30(2):311-327.
  92. Temme EH and Van Hoydonck PG. Tea consumption and iron status. Eur J ClinNutr. 2002;56(5):379-386.
  93. Mennen L, Hirvonen T, Arnault N, Bertrais S, Galan P, Hercberg S. Consumption of black, green and herbal tea and iron status in French adults. Eur J ClinNutr. 2007;61(10):1174-1179.
  94. Cheng TO. Green tea does not inhibit iron absorption. Int. J. Cardiol. 2009;133(1):112.
  95. Imai K and Nakachi K. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases.BMJ. 1995;310(6981):693-696.
  96. Samman S, Sandström B, Toft MB, et al. Green tea or rosemary extract added to foods reduces nonheme-iron absorption. Am J ClinNutr. 2001;73(3):607-612.
  97. Lovell MA, Xie C, Xiong S, Markesbery WR. Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. J. Alzheimers Dis. 2003;5(3):229-239.
  98. Suh JH, Moreau R, Heath, SH, Hagen TM. Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep. 2005;10(1):52-60.
  99. Mingorance C, Rodriguez-Rodriguez R, Justo ML, Herrera MD, de Sotomayor MA. Pharmacological effects and clinical applications of propionyl-L-carnitine.Nutr Rev. 2011;69(5):279-90.
  100. Lal A, Atamna W, Killilea DW, Suh JH, Ames BN. Lipoic acid and acetyl-carnitine reverse iron-induced oxidative stress in human fibroblasts. Redox Rep. 2008;13(1):2-10.
  101. Vanella A, Russo A, Acquaviva R, et al. L -propionyl-carnitine as superoxide scavenger, antioxidant, and DNA cleavage protector. Cell Biol. Toxicol. 2000;16(2):99-104.
  102. Reznick AZ, Kagan VE, Ramsey R, et al. Antiradical effects in L-propionylcarnitine protection of the heart against ischemia-reperfusion injury: the possible role of iron chelation. Arch. Biochem. Biophys. 1992;296(2):394-401.